Department of Surgery faculty participate in various sponsored multicenter clinical trials and serve as the site principal investigator of these clinical trials:
 

Joseph Carmichael, MD, “A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large- and Small-Bowel Resection”

Anthony Chau, MD, “CCR-23-02: DEFIANCE RCT of ClotTriever System vs. Anticoagulation in Deep Vein Thrombosis” and “CCR-23-24: EndurAnt Stent Graft system vs ExcluDer endoprothesis: A global, prospectiVe, rANdomized Clinical trial in sac rEgression (ADVANCE Study)”

Samuel Chen, MD, “CCR-23-85: A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular lesions located in the infrapoplitEal Arteries beLow the knee (DEEPER REVEAL)”

Theresa Chin, MD, “CCR-20-131: A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of the RECELL System Combined with Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction”

Oliver Eng, MD, “Alliance A022101/NRG-GI009: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur Trial)”

Roy Fujitani, MD: 

  • “A Phase 3 Study to Compare the Efficacy and Safety of Humacyte Human Acellular Vessel with that of an Autologous Arteriovenous Fistula in Subjects with End-Stage Renal Disease”
     
  • “A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacyte’s Human Acellular Vessel for Vascular Replacement or Reconstruction in Patients with Life or Limb-threatening Vascular Trauma”

David Imagawa, MD, PhD:

  • “An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma”
     
  • “A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma, Including FGFR2 Translocations Who Failed Previous Therapy”
     
  • “UCI 18-10: PACER (Pancreatic AdenoCarcinoma with Electron intraoperative Radiation Therapy): A Phase II Study of Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients with Pancreatic Cancer with Vascular Involvement”
     
  • “UCI-19-106: A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)”
     
  • “Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma”

Victor Joe, MD, “Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries”

Zeljka Jutric, MD, “Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial”

Nii-Kabu Kabutey, MD: 

  • “Randomized, Multicenter, Controlled Trial to Compare Best Endovascular Versus Best Surgical Therapy in Patients with Critical Limb Ischemia”
     
  • “A Prospective, Multicenter, Non-Blinded, Non-Randomized Study of the Relay PRO Thoracic Stent-Graft in Subjects with Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers”
     
  • “A Prospective, Multicenter, Non-Blinded, Non-Randomized Study of the RelayPro Thoracic Stent-Graft in Subjects with Traumatic Injury of the Descending Thoracic Aorta”
     
  • “CCR-20-159: Evaluation of a Closed Incision Negative Pressure Dressing (PREVENA) to Prevent Lower Extremity Amputation Wound Complications”
     
  • “Anchor Aneurysm Treatment Using the Aptus Heli-FX EndoAnchor System Global Registry”

Hari Keshava, MD, “UCI 21-221: Development of Personalized Immunotherapies for Esophageal Cancer”

Steven Mills, MD, “CCR-22-34: A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Post-Operative Ileus and Intra-Abdominal Adhesions in Subjects Undergoing Elective Bowel Resection (PROFILE)”

Jeffry Nahmias, MD, “CCR-21-123: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra / Beriplex]) to Improve Survival in Patients with Traumatic Injury and Acute Major Bleed”

Robert Redfield, MD: 

Sebastian Schubl, MD, “CCR-22-35: Zimmer Biomet Patient Outcome and Experience After Chest Wall Repair with RibFix Advantage”

Skandan Shanmugan, MD, “CCR-23-04: SPOTLITE: ProSPective ObservaTionaL Study on the Clinical Outcomes of Surgical InTErventions in Complex Fistulizing Conditions (CPF-CD, CD-RVF, CCF)”

Matthew Whealon, MD, “Multicenter Phase II Study of Transanal Total Mesorectal Excision (taTME) with Laparoscopic Assistance for Rectal Cancer”

Maki Yamamoto, MD, “UCI-21-106: A Phase 2 Open-label, Dose-Finding Study to Determine the Optimal Dose for Lymph Node Visualization Using ASP5354 in Participants with Breast Cancer or Melanoma Undergoing Sentinel Lymph Node Biopsy”